COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness
Matthew W Reynolds,Yiqiong Xie,Kendall B Knuth,Christina D Mack,Emma Brinkley,Stephen Toovey,Nancy A Dreyer
DOI: https://doi.org/10.2147/IDR.S373183
2022-09-03
Infection and Drug Resistance
Abstract:Matthew W Reynolds, 1 Yiqiong Xie, 1 Kendall B Knuth, 1 Christina D Mack, 1 Emma Brinkley, 1 Stephen Toovey, 2 Nancy A Dreyer 1 1 Real World Solutions, IQVIA, Cambridge, MA, USA; 2 Virology, Pegasus Research, London, UK Correspondence: Matthew W Reynolds, Real-World Solutions, IQVIA, 201 Broadway, Cambridge, MA, 02139, USA, Email Purpose: Coronavirus disease 2019 (COVID-19) has highlighted the need for new methods of pharmacovigilance. Here, we use adult community volunteers to obtain systematic information on vaccine effectiveness and the nature and severity of breakthrough infections. Methods: Between December 15, 2020 and September 16, 2021, 11,826 unpaid community-based volunteers reported the following information to an on-line registry: COVID-19 test results, vaccination (Pfizer, Moderna, or Johnson & Johnson) and COVID-19 symptoms. COVID-19 infections were described based on vaccination status at the time of infection: 1) fully vaccinated, 2) partially vaccinated (received first of two-dose vaccines or were 97%) fully vaccinated participants reported no symptoms or only mild symptoms compared to 89.3% of the unvaccinated cases. Only 1.4% of fully vaccinated participants reported experiencing at least 3 moderate-to-severe symptoms compared to 7.8% in the unvaccinated. Conclusion: Person-generated health data, also referred to as patient-reported outcomes, is a useful approach for quantifying breakthrough infections and their severity and for comparing vaccines. Trial Registration: Clinicaltrials.gov NCT04368065, EU PAS Register EUPAS36240. Keywords: COVID-19, vaccines, breakthrough infections, SARS-CoV-2, symptoms, patient-reported outcomes The three Coronavirus disease 2019 (COVID-19) vaccines authorized by the United States Food and Drug Administration (FDA) as of this writing have been found to be safe and highly efficacious in preventing symptomatic, laboratory-confirmed COVID-19 infections in randomized controlled trials. 1–3 But, as is not uncommon with even highly effective vaccines, these vaccines confer infection-permissive or "non-sterilizing" immunity, which may permit infection while preventing symptoms, and especially severe symptoms. 4 Infection in vaccinated persons is referred to as a "breakthrough" infection, defined by the US Centers for Disease Control and Prevention (CDC) as those who have detectable SARS-CoV-2 RNA or antigen on a respiratory specimen collected ≥14 days after completion of a vaccine regimen. 1 While cases of COVID-19 do occur after vaccination, an excess of breakthrough infections could suggest a lack of vaccine effectiveness, consistent with the FDA definition of an adverse event as including "failure to produce the expected pharmacologic action". 5 For COVID, these concerns may be exacerbated by the emergence of viral mutations conferring possible vaccine escape, including some known variants of concern, making prompt detection of lack of effectiveness a public health imperative. 6 While some serious safety concerns remain for COVID-19 vaccines, eg, anaphylaxis 7,8 and Guillain-Barre Syndrome, 9 lack of vaccine effectiveness is of particular importance given the potential risk of severe COVID-19 disease and mortality. Such information may also be useful for addressing the hesitancy occasioned by the accelerated development of these vaccines. 10,11 . While there are some reports quantifying the extent of breakthrough infections and severity of any associated symptoms based on surveillance or electronic medical record data, 12–19 person-generated data, sometimes called patient-reported health data or patient reported outcomes provide additional insights, especially for symptoms that may not occasion medical care. The objective of this work was to describe breakthrough infections in adults who received any of the three COVID-19 vaccines currently authorized for use in the US (BioNTech (Pfizer), Moderna, Inc. (Moderna), and Janssen Pharmaceuticals -Abstract Truncated-
pharmacology & pharmacy,infectious diseases